Tumor Markers /


Tumor markers are produced by the cancer tissue itself or at times by the body in response to cancer growth. Tumor markers are present in blood, urine or tissue and therefore can be used in conjunction with other tests and procedures to (1) detect and diagnose certain types of cancer, (2) predict and monitor a person’s response to certain treatments, and (3) detect recurrence. Tumor markers are powerful tools in therapy control and follow-up of cancer patients; however precision is a critical parameter when selecting an assay method.

Humor Diagnostica offers a wide range of tumor marker assays from different methodologies – ELISA, RIA, LUMI or automation through TRACE technology (Kryptor analyzer).

Tumor markers are grouped in the area of usage e.g. lung or colon cancer and include: CEA, AFP, CA19-9, CA125 II, CA15-3, Chromogranin A, NSE, Cyfra 21-1, SCC, hCG+β, PSA, Calcitonin, hTG and many other unique specialty biomarkers. Refer to tumor marker product schedule and tumor marker combination for therapy control and follow-up for a breakdown of the assay groups.

For more information on the unique precision features of the Kryptor analyzer, click here to download the Kryptor tumor marker precision brochure.Thermo Scientific™ B·R·A·H·M·S™ KRYPTOR™, offers unique biomarkers for instance Chromogranin A, Prolactin and High sensitive Tg.

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer characterized by neuroendocrine differentiated cells.

When progressing up to 40 % of prostate cancers develop neuroendocrine differentiation (NED).

Neuroendocrine prostate cancer cells usually do not secrete PSA, but Chromogranin A (CgA), and thus NEPC patients often show disproportionately low PSA values with elevated CgA.

Neuroendocrine Prostate Cancer is the major cause for (CRPC) Castration Resistant Prostate Cancer.  Initially the ooccurrence of neuroendocrine prostate cancer (NEPC) is low (< 1%) but during hormonal therapy incidence of NEPC increases significantly.  Blood CgA levels can be used to monitor neuroendocrine differentiation, treatment resistance to ADT or risk prognosis.